Can you take Flavoxate with Opicapone?
1 drug interaction and 12 additional warnings found for the following 2 drugs:
- flavoxate
- opicapone
Drug interactions
Moderate drug interactions
Moderate:
flavoxATE opicapone
Applies to: flavoxate and opicapone
Using flavoxATE together with opicapone may increase side effects such as dizziness, drowsiness, confusion, and difficulty concentrating. Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:
flavoxATE Food/Lifestyle
Applies to: flavoxate
Alcohol can increase the nervous system side effects of flavoxATE such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with flavoxATE. Do not use more than the recommended dose of flavoxATE, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Moderate:
opicapone Food/Lifestyle
Applies to: opicapone
Food may delay and reduce the absorption of opicapone, which may lead to lower blood levels of the medication and possibly reduced effectiveness. You should take opicapone once daily at bedtime. Do not eat food for at least 1 hour before and at least 1 hour after taking opicapone. Talk to your doctor or pharmacist if you have any questions or concerns.
Disease interactions
10 potential interactions Applies to: 10 conditions, including Hypotension, Psychosis, Lactose Intolerance, Urinary Retention, and Liver Disease.
Adrenal Tumor
Major:
opicapone
Opicapone has a major potential interaction with Adrenal Tumor.
The use of opicapone is contraindicated in patients with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
Gastrointestinal Obstruction
Major:
flavoxate
flavoxATE has a major potential interaction with Gastrointestinal Obstruction.
The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy. Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.
Glaucoma/Intraocular Hypertension
Moderate:
flavoxate
flavoxATE has a moderate potential interaction with Glaucoma/Intraocular Hypertension.
Flavoxate exerts mydriatic activity that can induce increased intraocular pressure and result in angle-closure (narrow angle) glaucoma. Therapy with flavoxate should be administered cautiously in patients with angle-closure glaucoma.
Hypotension
Moderate:
opicapone
Opicapone has a moderate potential interaction with Hypotension.
Opicapone may cause orthostatic blood pressure changes including fainting and dizziness and patients should be advised to avoid standing rapidly after sitting or lying down. Caution is advised in patients with hypotension.
Lactose Intolerance
Moderate:
opicapone
Opicapone has a moderate potential interaction with Lactose Intolerance.
Opicapone formulations contain lactose. Caution is advised if used in patients with lactose intolerance.
Liver Disease
Moderate:
opicapone
Opicapone has a moderate potential interaction with Liver Disease.
The mean overall plasma exposure (AUC) of opicapone increased by 84% in patients with moderate (Child-Pugh Class B) liver dysfunction. A dosage adjustment is required on these patients. The pharmacokinetics of this drug have not been studied in patients with severe liver dysfunction (Child-Pugh: C). Caution is advised.
Pheochromocytoma
Major:
opicapone
Opicapone has a major potential interaction with Pheochromocytoma.
The use of opicapone is contraindicated in patients with pheochromocytoma, paraganglioma, or other catecholamine secreting neoplasms.
Psychosis
Major:
opicapone
Opicapone has a major potential interaction with Psychosis.
Opicapone may cause impulse control disorders including pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating, and compulsive eating. Patients with a major psychotic disorder should ordinarily not be treated with this drug because of the risk of exacerbating the psychosis with an increase in central dopaminergic tone.
Renal Dysfunction
Moderate:
opicapone
Opicapone has a moderate potential interaction with Renal Dysfunction.
The pharmacokinetics of opicapone have not been studied in patients with end stage renal disease. Caution is advised.
Urinary Retention
Major:
flavoxate
flavoxATE has a major potential interaction with Urinary Retention.
The use of flavoxate is contraindicated in patients with GI obstruction, ileus, atony, and obstructive uropathy. Flavoxate exerts direct antispasmodic effects on smooth muscles and possesses weak anticholinergic activity.
Report options
More resources
flavoxate
A total of 344 drugs are known to interact with flavoxate.
- Flavoxate is in the drug class urinary antispasmodics.
- Flavoxate is used to treat the following conditions:
opicapone
A total of 279 drugs are known to interact with opicapone.
- Opicapone is in the drug class dopaminergic antiparkinsonism agents.
- Opicapone is used to treat Parkinson's Disease.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.